New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer

doi:10.5320/wjr.v6.i2.57

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11048)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

545

WORD

278

HTML

4722

Figures (1-2)

230

Tables (1-3)

250

Sum=6025

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

709

Download

1683

Sum=2392

Publishing Process of This Article

Item

Count

Browse

960

Download

1671

Sum=2631

Jul 28, 2016 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Frontier

World J Respirol. Jul 28, 2016; 6(2): 57-62
Published online Jul 28, 2016. doi: 10.5320/wjr.v6.i2.57

Table 2 Evaluation of outcome of tyrosine kinase inhibitor’s treatment according to epidermal growth factor receptor mutations or epidermal growth factor receptor wild-type[20,29]

EGFR mutations		RR %	PFS (mo)	OS (mo)
Most common	Del exon 9	74	8.5	19.6
Most common	L858R exon 21	74	8.5	19.6
Less frequent	G719X exon18	53.3	8.1	16.4
Less frequent	L861Q exon 21	60	6	15.2
Uncommon	V769M	20	1.6	11.1
Uncommon	A871E	20	1.6	11.1
EGFR wild-type		16.5	2	10.4

EGFR: Epidermal growth factor receptor; RR: Response rate; PFS: Progression free survival; OS: Overall survival.

Citation: Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62
URL: https://www.wjgnet.com/2218-6255/full/v6/i2/57.htm
DOI: https://dx.doi.org/10.5320/wjr.v6.i2.57